Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, the Lmdd-MPFG vaccine activates the NF-κB pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway.
|
31659256 |
2020 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In immunohistochemical analysis, AGG-treated tumor displays higher caspase 3 expression and less p62 and NRF2 expression in comparison to the control.
|
31715238 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we investigated some mechanistic aspects of these effects.In mammary tumors bearing-dogs, i.m. injections of p62 plasmid reduced tumor sizes and their aggressive potential in 5 out of 6 animals, with one carcinoma switching to adenoma.
|
31754084 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a tumor-suppression mechanism, autophagy deficiency is common in tumors, which results in aberrant accumulation of p62 and activates p62-regulated pathways, such as activation of mTOR in nutrient sensing, and the activation of the Keap1-Nrf2 pathway for antioxidant stress, which are associated with cancer development.
|
31802896 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Apc<sup>Min/+</sup></i> mice when infected with CR and <i>BLT1<sup>-/-</sup>;Apc<sup>Min/+</sup></i> mice, exhibited similar co-localization of p62 with LC3B and Dclk1 within the tumors.
|
31040926 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the role of p62 in tumour development depends on the interacting factors it recruits and its precise regulatory mechanism remains unclear.
|
30941888 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo.
|
30275562 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Evidence has shown that p62 is upregulated in different cancers and promotes tumour growth, such as in liver cancer and lung cancer.
|
30793399 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both the metastatic and recurrent tumor tissues expressed less p62 than the patient-matched primary tumor.
|
29699801 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Through activating the protein kinase C iota (PKCiota)-S-phase kinase-associated protein 2 (SKP2) signaling pathway, p62 enhances cell apoptosis resistance and colony formation in vitro and tumor growth in mouse models.
|
29551772 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, autophagy markers LC3II/I (<i>p</i> < 0.05), Beclin-1 (<i>p</i> < 0.01), and P62 (<i>p</i> < 0.05) increased in the skeletal muscle of tumor-bearing mice.
|
30713500 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p62 proteins were elevated and mainly located in the cytoplasm in some types of tumor compared with the normal tissues.
|
30410612 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for the autophagy markers LC3B and p62 was applied on tumor tissue from 149 EAC patients treated with neoadjuvant chemotherapy, including pre- and post-therapeutic samples (62 matched pairs).
|
29897944 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Metabolic reprogramming of the tumor microenvironment by p62 and its partners.
|
29702207 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Publisher Correction: p62 - a new metabolic tumour suppressor.
|
30072811 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Also, the siRNA-MALAT-1 group had a decreased tumor volume and weight in the subcutaneous tumor xenograft model in nude mice, and increased LC3-II/LC3-I expression but decreased p62 expression in tumor tissues when compared with the blank group and the siNC group (all P<0.05).
|
28292022 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ATF4 upregulation by p62 deficiency in the stroma activates glucose carbon flux through a pyruvate carboxylase-asparagine synthase cascade that results in asparagine generation as a source of nitrogen for stroma and tumor epithelial proliferation.
|
28988820 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings show how p62 helps maintain intracellular pools of GSH needed to limit mitochondrial dysfunction in tumor cells with elevated mTORC1, highlighting p62 and redox homeostasis as nodal vulnerabilities for therapeutic targeting in these tumors.<i></i>.
|
28512249 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NF-κB Signaling Activation Induced by Chloroquine Requires Autophagosome, p62 Protein, and c-Jun N-terminal Kinase (JNK) Signaling and Promotes Tumor Cell Resistance.
|
28082672 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of LSD1 reduces both tumor growth and p62 protein degradation <i>in vivo</i>.
|
29088798 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further validation was done in vivo by conducting mouse tumor xenograft experiments, where HMGB1 knockdown tumors showed a significantly better (P < 0.001) response to radiotherapy and decreased autophagy (shown by P62 staining) as compared with controls.
|
26719575 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations.
|
26268733 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our studies demonstrate that p62 and autophagy synergize to promote tumor growth, suggesting that inhibition of both pathways could be more effective than targeting either alone for cancer therapy.
|
24888590 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, p62 is an anti-inflammatory tumor suppressor that acts through the modulation of metabolism in the tumor stroma.
|
25002027 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In mice, p62 up-regulation promotes tumor cell growth and metastasis in a Twist1-dependent manner.
|
24927592 |
2014 |